Target validation to biomarker development: Focus on RNA interference

Molecular Diagnosis and Therapy

Volumn 12, Issue 2, 2008, Pages 63-70

  Colombo, Riccardo ^a   Moll, Jürgen ^a  

^a NERVIANO MEDICAL SCIENCES   (Italy)

Author keywords

Biomarkers; Research and development; RNA interference, general; Small interfering RNA, general

Indexed keywords

ADENOVIRUS VECTOR; ANTISENSE OLIGODEOXYNUCLEOTIDE; BRCA1 PROTEIN; CARCINOEMBRYONIC ANTIGEN; GLYCOGEN SYNTHASE KINASE 3BETA; LENTIVIRUS VECTOR; LIPOSOME; PACLITAXEL; PARVOVIRUS VECTOR; PROSTATE SPECIFIC ANTIGEN; RIBOZYME; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; SURVIVIN;

AMINO ACID SUBSTITUTION; CANCER CELL; CELL DIFFERENTIATION; CYTOTOXICITY; DRUG TARGETING; EWING SARCOMA; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE LIBRARY; GENE MUTATION; GENE SEQUENCE; GENE SILENCING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; MEDICAL RESEARCH; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVIEW; RNA INTERFERENCE; RNA STABILITY; RNA STRUCTURE; RNA TRANSLATION;

EID: 42449134982     PISSN: 11771062     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256271     Document Type: Review

References (73)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004; 3 (8): 711-5
2. Same old story? Nat Rev Drug Discov 2007; 6 (2): 97
3. Collins I, Workman P. New approaches to molecular cancer therapeutics. Nat Chem Biol 2006; 2 (12): 689-700
4. Benson JD, Chen YN, Cornell-Kennon SA, et al. Validating cancer drug targets. Nature 2006; 441 (7092): 451-6
5. Sawyers CL. Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 2003; 17 (24): 2998-3010
6. Sanger Institute. Cancer gene census [online]. Available from URL: http://www.sanger.ac.uk/genetics/CGP/Census/ [Accessed 2008 Feb 25]
7. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417 (6892): 949-54
8. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005; 436 (7047): 117-22
9. Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp Cell Res 1999; 253 (1): 78-87
10. Kitayama H, Tsujimura T, Matsumura I, et al. Neoplastic transformation of normal hematopoietic cells by constitutively activating mutations of c-kit receptor tyrosine kinase. Blood 1996; 88 (3): 995-1004
11. Li QX, Tan P, Ke N, et al. Ribozyme technology for cancer gene target identification and validation. Adv Cancer Res 2007; 96: 103-43
12. Kurreck J. Antisense technologies: improvement through novel chemical modifications. Eur J Biochem 2003; 270 (8): 1628-44
13. Pendergrast PS, Marsh HN, Grate D, et al. Nucleic acid aptamers for target validation and therapeutic applications. J Biomol Tech 2005; 16 (3): 224-34
14. Bennett CF. Efficiency of antisense oligonucleotide drug discovery. Antisense Nucleic Acid Drug Dev 2002; 12 (3): 215-24
15. Scherer LJ, Rossi JJ. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 2003; 21 (12): 1457-65
16. Napoli C, Lemieux C, Jorgensen R. Introduction of a Chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990; 2 (4): 279-89
17. Cerutti H, Casas-Mollano JA. On the origin and functions of RNA-mediated silencing: from protists to man. Curr Genet 2006; 50 (2): 81-99
18. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391 (6669): 806-11
19. Kavi HH, Fernandez HR, Xie W, et al. RNA silencing in Drosophila. FEBS Lett 2005; 579: 5940-9
20. Qi Y, Hannon GJ. Uncovering RNAi mechanisms in plants: biochemistry enters the foray. FEBS Lett 2005; 579: 5899-903
21. Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411 (6836): 494-8
22. Kim DH, Rossi JJ. Strategies for silencing human disease using RNA interference. Nat Rev Genet 2007; 8 (3): 173-84
23. Bernstein E, Caudy AA, Hammond SM, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409 (6818): 363-6
24. Amarzguioui M, Rossi JJ, Kim D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett 2005; 579 (26): 5974-81
25. Berezikov E, Guryev V, van de BJ, et al. Phylogenetic shadowing and computational identification of human microRNA genes. Cell 2005; 120 (1): 21-4
26. Bartel DP, Chen CZ. Micromanagers of gene expression: the potentially widespread influence of metazoan microRNAs. Nat Rev Genet 2004; 5 (5): 396-400
27. Esquela-Kerscher A, Slack FJ. Oncomirs: microRNAs with a role in cancer. Nat Rev Cancer 2006; 6 (4): 259-69
28. Wienholds E, Plasterk RH. MicroRNA function in animal development. FEBS Lett 2005; 579 (26): 5911-22
29. Ui-Tei K, Naito Y, Takahashi F, et al. Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference. Nucleic Acids Res 2004; 32 (3): 936-48
30. Kim DH, Behlke MA, Rose SD, et al. Synthetic dsRNA dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005; 23 (2): 222-6
31. Sledz CA, Holko M, de Veer MJ, et al. Activation of the interferon system by short-interfering RNAs. Nat Cell Biol 2003; 5 (9): 834-9
32. de Fougerolles A, Vornlocher HP, Maraganore J, et al. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6 (6): 443-53
33. McCaffrey AP, Meuse L, Pham TT, et al. RNA interference in adult mice. Nature 2002; 418 (6893): 38-9
34. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432: 173-8
35. Grimm D, Kay MA. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time? J Clin Invest 2007; 117: 3633-41
36. Zimmermann TS, Lee AC, Akinc A, et al. RNAi-mediated gene silencing in non-human primates. Nature 2006; 441 (7089): 111-4
37. Doench JG, Petersen CP, Sharp PA. siRNAs can function as miRNAs. Genes Dev 2003; 17 (4): 438-42
38. Jackson AL, Burchard J, Schelter J, et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006; 12 (7): 1179-87
39. Jackson AL, Burchard J, Leake D, et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006; 12 (7): 1197-205
40. Mook OR, Baas F, de Wissel MB, et al. Evaluation of locked nucleic acid-modified small interfering RNA in vitro and in vivo. Mol Cancer Ther 2007; 6 (3): 833-43
41. Iorns E, Lord CJ, Turner N, et al. Utilizing RNA interference to enhance cancer drug discovery. Nat Rev Drug Discov 2007; 6 (7): 556-68
42. Berns K, Hijmans EM, Mullenders J, et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428 (6981): 431-7
43. Kittler R, Pelletier L, Heninger AK, et al. Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol 2007; 9 (12): 1401-12
44. Moffat J, Grueneberg DA, Yang X, et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 2006; 124 (6): 1283-98
45. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005; 7 (6): 591-600
46. Krausz E. High-content siRNA screening. Mol Biosyst 2007; 3 (4): 232-40
47. Neumann B, Held M, Liebel U, et al. High-throughput RNAi screening by time-lapse imaging of live human cells. Nat Methods 2006; 3 (5): 385-90
48. Zheng L, Liu J, Batalov S, et al. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci U S A 2004; 101 (1): 135-40
49. Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006; 2 (4): 202-6
50. Draviam VM, Stegmeier F, Nalepa G, et al. A functional genomic screen identifies a role for TAO1 kinase in spindle-checkpoint signalling. Nat Cell Biol 2007; 9 (5): 556-64
51. Ngo VN, Davis RE, Lamy L, et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441 (7089): 106-10
52. Sarthy AV, Morgan-Lappe SE, Zakula D, et al. Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther 2007; 6 (1): 269-76
53. Rottmann S, Wang Y, Nasoff M, et al. A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A 2005; 102 (42): 15195-200
54. Collins CS, Hong J, Sapinoso L, et al. A small interfering RNA screen for modulators of tumor cell motility identifies MAP4K4 as a promigratory kinase. Proc Natl Acad Sci U S A 2006; 103 (10): 3775-80
55. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 (7035): 917-21
56. Gartel AL, Kandel ES. RNA interference in cancer. Biomol Eng 2006; 23 (1): 17-34
57. Wacheck V, Losert D, Gunsberg P, et al. Small interfering RNA targeting bcl-2 sensitizes malignant melanoma. Oligonucleotides 2003; 13 (5): 393-400
58. Spankuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, et al. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst 2002; 94 (24): 1863-77
59. Choudhury A, Charo J, Parapuram SK, et al. Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 2004; 108 (1): 71-7
60. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002; 2 (3): 243-7
61. Lage H. Potential applications of RNA interference technology in the treatment of cancer. Future Oncol 2005; 1 (1): 103-13
62. Williams NS, Gaynor RB, Scoggin S, et al. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res 2003; 9 (3): 931-46
63. Hoeflich KP, Gray DC, Eby MT, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006; 66 (2): 999-1006
64. Pan Q, Bao LW, Kleer CG, et al. Protein kinase C epsilon is a predictive biomarker of aggressive breast cancer and a validated target for RNA interference anticancer therapy. Cancer Res 2005; 65 (18): 8366-71
65. Bae KM, Wang H, Jiang G, et al. Protein kinase C epsilon is overexpressed in primary human non-small cell lung cancers and functionally required for proliferation of non-small cell lung cancer cells in a p21/Cip1-dependent manner. Cancer Res 2007; 67 (13): 6053-63
66. Pan Q, Bao LW, Teknos TN, et al. Targeted disruption of protein kinase C epsilon reduces cell invasion and motility through inactivation of RhoA and RhoC GTPases in head and neck squamous cell carcinoma. Cancer Res 2006; 66 (19): 9379-84
67. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95
68. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003; 2 (7): 566-80
69. Ackermann BL, Hale JE, Duffin KL. The role of mass spectrometry in biomarker discovery and measurement. Curr Drug Metab 2006; 7 (5): 525-39
70. Ayers M, Fargnoli J, Lewin A, et al. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Cancer Res 2007; 67 (14): 6899-906
71. Kovar H. Context matters: the hen or egg problem in Ewing's sarcoma. Semin Cancer Biol 2005; 15 (3): 189-96
72. Stegmaier K, Wong JS, Ross KN, et al. Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in Ewing sarcoma. PLoS Med 2007; 4 (4): e122
73. Nobelprize.org. The Nobel Prize in physiology or medicine [online]. Available from URL: http://nobelprize.org/nobel_prizes/medicine/laureates/2006/ [Accessed 2008 Feb 25]